Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

Pierre Rocca; Jérôme Dumortier; Philippe Tanière; Serge Duperret; Thierry Vial; Vincent Cottin; Bertrand Delafosse; Jean Yves Scoazec; Olivier Boillot

Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

Translated title of the contribution: Induced interstitial pneumonitis: Role of pegylated interferon alpha 2b

Pierre Rocca, Jérôme Dumortier, Philippe Tanière, Serge Duperret, Thierry Vial, Vincent Cottin, Bertrand Delafosse, Jean Yves Scoazec, Olivier Boillot

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

Translated title of the contribution	Induced interstitial pneumonitis: Role of pegylated interferon alpha 2b
Original language	French
Pages (from-to)	405-408
Number of pages	4
Journal	Gastroenterologie Clinique et Biologique
Volume	26
Issue number	4
Publication status	Published - 5 Jun 2002
Externally published	Yes

Cite this

@article{365cd654fd05436f8ee32d0baaf4db73,

title = "Forme pegyl{\'e}e de l'interf{\'e}ron alpha 2b et pneumopathies interstitielles diffuses",

abstract = "Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.",

author = "Pierre Rocca and J{\'e}r{\^o}me Dumortier and Philippe Tani{\`e}re and Serge Duperret and Thierry Vial and Vincent Cottin and Bertrand Delafosse and Scoazec, {Jean Yves} and Olivier Boillot",

year = "2002",

month = jun,

day = "5",

language = "Fran{\c c}ais",

volume = "26",

pages = "405--408",

journal = "Gastroenterologie Clinique et Biologique",

issn = "0399-8320",

number = "4",

}

TY - JOUR

T1 - Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

AU - Rocca, Pierre

AU - Dumortier, Jérôme

AU - Tanière, Philippe

AU - Duperret, Serge

AU - Vial, Thierry

AU - Cottin, Vincent

AU - Delafosse, Bertrand

AU - Scoazec, Jean Yves

AU - Boillot, Olivier

PY - 2002/6/5

Y1 - 2002/6/5

N2 - Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

AB - Pulmonary complications of alpha interferon are rare. We report two cases of lung complications in liver transplantation patients for HCV related cirrhosis. After switching from interferon alpha to pegylated interferon alpha 2b, one patient developed a BOOP (Bronchiolitis Obliterans Organizing Pneumonia) and the other severe interstitial pneumonitis. We discuss the causes of these rare pulmonary alpha-interferon induced complications and the different way to suggest that the pegylated interferon alpha 2b could be related to the risk of pulmonary toxicity of this treatment.

UR - http://www.scopus.com/inward/record.url?scp=0036105513&partnerID=8YFLogxK

M3 - Article

C2 - 12070414

AN - SCOPUS:0036105513

SN - 0399-8320

VL - 26

SP - 405

EP - 408

JO - Gastroenterologie Clinique et Biologique

JF - Gastroenterologie Clinique et Biologique

IS - 4

ER -

Forme pegylée de l'interféron alpha 2b et pneumopathies interstitielles diffuses

Abstract

Other files and links

Cite this